SVA — Sernova Biotherapeutics Share News
0.000.00%
Last trade - 00:00- CA$43.43m
- CA$57.97m
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints
Brief: Sernova Biotherapeutics Receives FDA Clearance For Ind Application For Its Cell Pouch Bio-Hybrid Organ With Autograft Thyroid Cells In Patients With Hypothyroidism
Brief: Sernova Update On Strategic Initiatives
Brief: Sernova Corp. Announces Appointment Of New Chief Executive Officer
Brief: Sernova Says Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial
Brief: Sernova To Provide Two Program Updates
Brief: Sernova Provides Development Update On Proprietary Cellular Conformal Coating Technology
Brief: Sernova Corporation Announces The Appointment Of Cynthia Pussinen As CEO
Brief: Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data For Cell Pouch System
Brief: Sernova Announces Executive Alignment And Appoints New Board Chair
Brief: Two Independent Proxy Advisory Firms Recommend Sernova’s Shareholders Vote For All Management Nominees On Management’s White Proxy
Brief: Group Of Shareholders Of Sernova Corporation - Regarding Management Compensation, Increases Recommended By Sernova Corp Are "Unreasonable"
Brief: ISS Recommends Senova's Shareholders Vote For All Management Nominees
Brief: Sernova Announces Initial Islet Transplantation In First Two Patients Enrolled For Type 1 Diabetes Treatment Trial
Brief: Sernova Announces Advancements With Its Novel Cell Pouch System
Brief: Sernova Announces CEO Succession Plan And Expanded Management Team